Literature DB >> 18777114

Signal pathway involved in inhibition by lipoxin A(4) of production of interleukins induced in endothelial cells by lipopolysaccharide.

Sheng-Hua Wu1, P-Y Liao, L Dong, Z-Q Chen.   

Abstract

OBJECTIVE AND
DESIGN: We examine whether lipoxin A(4) (LXA(4)) inhibits production of interleukins (ILs) in endothelial cells and what signal pathway might participate in the actions of LXA(4).
METHODS: Cultured pulmonary microvascular endothelial cells (PMVEC) were treated with lipopolysaccharide (LPS), with or without preincubation with LXA(4).
RESULTS: The results showed that LPS induced production of IL-1beta, IL-6 and IL-8 in rat PMVEC, upregulated the expressions of myeloid differentiation factor 88 (MyD88), phosphorylated p38 and p42/44 mitogen-activated protein kinase (MAPK), phosphorylated phosphoinositide 3-kinase (PI3-K), DNA-binding activities of nuclear factor-kappa B (NF-kappaB) and activator protein-1(AP-1). The blockade of p38 MAPK, p42/44 MAPK, PI3-K, NF-kappaB or AP-1 partially inhibited production of IL-1beta, IL-6 and IL-8 stimulated by LPS, respectively. LXA(4) significantly inhibited LPS-stimulated secretion of protein and expressions of mRNA of IL-1beta, IL-6 and IL-8, activation of p38 MAPK, p42/44 MAPK, PI3-K, NF-kappaB and AP-1 but not MyD88 in PMVEC.
CONCLUSIONS: LXA(4) inhibits synthesis of IL-1beta, IL-6 and IL-8 in PMVEC and this antagonism is related to PI3-K, p38 and p42/44 MAPK, NF-kappaB and AP-1 pathway-dependent signal transduction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18777114     DOI: 10.1007/s00011-008-7147-1

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  17 in total

Review 1.  Possible role for anisodamine in organophosphate poisoning.

Authors:  Arik Eisenkraft; Avshalom Falk
Journal:  Br J Pharmacol       Date:  2016-04-22       Impact factor: 8.739

2.  17(R)-Resolvin D1 differentially regulates TLR4-mediated responses of primary human macrophages to purified LPS and live E. coli.

Authors:  Christine D Palmer; Christy J Mancuso; Jerrold P Weiss; Charles N Serhan; Eva C Guinan; Ofer Levy
Journal:  J Leukoc Biol       Date:  2011-06-07       Impact factor: 4.962

3.  Lipoxin A4 suppresses the development of endometriosis in an ALX receptor-dependent manner via the p38 MAPK pathway.

Authors:  Rongfeng Wu; Weidong Zhou; Shuo Chen; Yan Shi; Lin Su; Maobi Zhu; Qionghua Chen; Qingxi Chen
Journal:  Br J Pharmacol       Date:  2014-11       Impact factor: 8.739

4.  A lipoxin A4 analog ameliorates blood-brain barrier dysfunction and reduces MMP-9 expression in a rat model of focal cerebral ischemia-reperfusion injury.

Authors:  Yan Wu; Yan-Ping Wang; Peipei Guo; Xi-Hong Ye; Jie Wang; Shi-Ying Yuan; Shang-Long Yao; You Shang
Journal:  J Mol Neurosci       Date:  2011-08-16       Impact factor: 3.444

Review 5.  International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.

Authors:  Richard D Ye; François Boulay; Ji Ming Wang; Claes Dahlgren; Craig Gerard; Marc Parmentier; Charles N Serhan; Philip M Murphy
Journal:  Pharmacol Rev       Date:  2009-06-04       Impact factor: 25.468

6.  BML-111 Attenuates Renal Ischemia/Reperfusion Injury Via Peroxisome Proliferator-Activated Receptor-α-Regulated Heme Oxygenase-1.

Authors:  Sheng-Hua Wu; Xiao-Qing Chen; Jing Lü; Ming-Jie Wang
Journal:  Inflammation       Date:  2016-04       Impact factor: 4.092

7.  n-3 and n-6 Fatty acids are independently associated with lipoprotein-associated phospholipase A2 in the Multi-Ethnic Study of Atherosclerosis.

Authors:  Brian T Steffen; Lyn M Steffen; Shuang Liang; Russell Tracy; Nancy Swords Jenny; Michael Y Tsai
Journal:  Br J Nutr       Date:  2013-04-03       Impact factor: 3.718

8.  Lipoxin A4-induced heme oxygenase-1 protects cardiomyocytes against hypoxia/reoxygenation injury via p38 MAPK activation and Nrf2/ARE complex.

Authors:  Xiao-Qing Chen; Sheng-Hua Wu; Yu Zhou; Yan-Rong Tang
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

9.  Lipoxins and aspirin-triggered lipoxin alleviate bone cancer pain in association with suppressing expression of spinal proinflammatory cytokines.

Authors:  Shan Hu; Qi-Liang Mao-Ying; Jun Wang; Zhi-Fu Wang; Wen-Li Mi; Xiao-Wei Wang; Jian-Wei Jiang; Ya-Lin Huang; Gen-Cheng Wu; Yan-Qing Wang
Journal:  J Neuroinflammation       Date:  2012-12-26       Impact factor: 8.322

10.  A role for lipoxin A₄ as an anti-inflammatory mediator in the human endometrium.

Authors:  Linsay J Macdonald; Sheila C Boddy; Fiona C Denison; Kurt J Sales; Henry N Jabbour
Journal:  Reproduction       Date:  2011-05-09       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.